Affinity reagents against tumour-associated extracellular molecules and newforming vessels.

Here we report some recent results of tumour targeting using extracellular matrix components of tumour stroma as targets. The possibility of using human recombinant antibodies in tumour targeting is also described. Preliminary results indicate that neovasculature markers can be targeted by recombinant antibodies and that they allow long residence time in tumours, thus exploiting the avidity properties of multivalent recombinant fragments.